ResistancePlus® MG

M. genitalium (Mgen) + macrolide resistance

Enabling Resistance Guided Therapy



Resistance Guided Therapy Increases Cure Rate¹

- Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.¹
- Detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.²
- Macrolide resistance testing is recommended by International,
 British, and Australian guidelines on Mgen infection.³⁻⁶





Resistance & Mycoplasma genitalium

- Mycoplasma genitalium (Mgen) is a sexually transmitted infection causing nongonococcal urethritis (NGU) and cervicitis, and is associated with pelvic inflammatory disease (PID).¹
- Prevalence of Mgen infections in the general population ranges from 1-3%, with an increased incidence in men with NGU (10-20%).^{6,7}
- Mgen is more prevalent than gonorrhoea and presents clinically similar symptoms to chlamydia

 leading to potential mistreatment and increased resistance.^{8,9}
- Mgen is commonly detected in rectal samples, is often asymptomatic, and exhibits high rates of macrolide resistance.^{2,6,10}

Rectal Mgen 8.9% Anorectum is the most common infection site for Mgen²

Rectal resistance

High percentage of anorectal infections harbour macrolide resistance

HIV+ MSM

Rates of Mgen **significantly higher** in HIV-positive MSM compared to other STIs¹⁰

"Although the subclinical nature of Mgen in the rectum questions its significance, the high prevalence seen at this site could be a potential source of onward urethral transmission. Future work should assess the need for appropriate screening and treatment of MG infection in MSM, particularly those with HIV infection and high-risk sexual behaviour."¹⁰



ResistancePlus® MG

A flexible and cost effective solution for your laboratory

- A single well test, combining Mgen detection and macrolide resistance a clear advantage compared with detection-only tests.
- Easily implemented into your existing workflow, with minimal disruption.
- Pack sizes to suit your laboratory throughput, minimising reagent wastage.
- Positive controls available as well as amplification control material to enable testing from pre-extracted samples.



Test	Resistance Detection	Time Of Sample To Answer	
ResistancePlus® MG	Yes	3 hours 10 minutes	
Competitor D	Yes	7 hours 10 minutes	
Competitor F	No	3 hours 10 minutes	
Competitor S	No	4 hours	

† Total time calculated using over-lapping workflow of manual and automated steps.

ResistancePlus[®] MG is a multiplex qPCR test for detection of Mgen and five azithromycin resistance markers, validated for a range of specimen types including anorectal swabs.¹¹ Powered by proprietary *PlexPCR*[®] technologies demonstrating improved multiplex performance compared with other probe-based tests.¹²

Single-well **Plex**PCR[®] Test

Channel	Target	
1	M. genitalium (MgPa)	
2	23S rRNA (A2058T, A2058C, A2058G, A2059C, A2059G)	
3	Internal Control	

Demonstrated clinical performance³

	MG Detection	Resistance Markers
Sensitivity	98%	92.5%
Sensitivity	100%	100%

Validated with urine, multiple swabs (anal, rectal, cervical, endocervical, vaginal, urethral, pharyngeal) and extracts (using *PlexPCR** Amplification Control).¹¹

SpeeDx Analysis ResistancePlus® MG

The complete solution includes validated software for automated result calling and simple sample processing. Supporting rapid, routine diagnostics with quality control, searchable databases, audit-trail, and user traceability. High security and GDPR compliant with LIS compatibility.

ResistancePlus® MG Positive Control

One control covers all your needs - Mgen detection and 5 mutations conferring macrolide resistance.

Product	Compatible	Size	Cat#
	LC480 II	100 reactions	20001L-01
Resistance Plus® MG ⁺		25 reactions	2000125
	ABI 7500/ 7500 Fast/Dx	100 reactions	2000201
		25 reactions	2000225
	CFX96 IVD/ CFX96 Touch	100 reactions	2000301
		25 reactions	2000325
ResistancePlus® MG Positive Control	All platforms	10 reactions	95001
PlexPCR® Amplification Control	All platforms	400 reactions	90002

References: 1. Read TRH et al. CID 2019; 68(4):554-560 2. Couldwell DL et al. Sex Transm Infect. 2018 Mar 22. pii: sextrans-2017-053480. doi: 10.1136 3. Jensen J, Cusini, M, Gomberg, M. 2016 European guideline on Mycoplasma genitalium infections. 4. Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. 5. Australian STI Management Guidelines – Mycoplasma genitalium 2018. 6. Soni S et. al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018) 7. Baumann L et al. Sex Transm Infect 2018;94:255-262. 8. Manhart LE et al. Am J Public Health. 2007;97(6):1118-25. 9. Bradshaw CS et al. J Infect Dis. 2017;216 (suppl_2):S412-S419. 10. Soni S. Sex Transm Infect. 2010 Feb;86(1):21-4. 11. ResistancePlus[®] MG Instructions for use 12. Tan LY et al, PLOS ONE. 2017; 12(1): e0170087 *Not for sale in USA. ResistancePlus[®] MG RistractPlus[®] MG Instructions for use 12. Tan LY et al, PLOS ONE. 2017; 12(1): e0170087 *Not for Other copyright and trademarks are the property of the respective owners. SpeeDx Pty. Ltd. products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/ patents for comprehensive patent information.

Australia - SpeeDx Pty. Ltd. +61 (0)2 9209 4170

sales@speedx.com.au

Suite G16, National Innovation Centre 4 Cornwallis Street, Sydney NSW 2015 Australia

Europe - SpeeDx Ltd.

+44 (0)333 577 5210

sales.uk@speedx.com.au

Kemp House 152-160 City Road London EC1V 2NX United Kingdom



Find out more plexpcr.com